id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_cruog5sfurhtpibtowvk6boay4	Basil M Hantash	A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma	2009.0	4	.pdf	application/pdf	2483	325	66	study was conducted to assess the effects of a novel proprietary synthetic oligopeptide (Lumixyl, Emed, Inc., Westlake Village, CA) on the appearance of facial melasma. the overall facial appearance of study participants and their respective satisfaction with their improvements or lack thereof. of twice-daily topical application of this oligopeptide (0.01% w/w) on moderate, recalcitrant melasma over a 16-week course. female participants with Fitzpatrick phototype IV and moderate recalcitrant melasma enrolled and completed the study. in melasma and overall facial aesthetics as well as assessment of volunteer satisfaction was measured using 10and five-point grading scales, respectively. statistically significant improvement in the appearance of melasma and overall facial aesthetics with high patient satisfaction. Two physicians graded improvement in the appearance of melasma in a blinded manner using a 10-point scale Blinded volunteer and physician assessments indicate that twice daily oligopeptide treatment improvement in their facial melasma after 16 weeks.	./cache/work_cruog5sfurhtpibtowvk6boay4.pdf	./txt/work_cruog5sfurhtpibtowvk6boay4.txt